Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial. Borgers JSW, Lenkala D, Kohler V, Jackson EK, et al. Nat Med 2025 Jan 3. doi: 10.1038/s41591-024-03418.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Borgers JSW, Lenkala D, Kohler V, Jackson EK, et al. Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial. Nat Med 2025 Jan 3. doi: 10.1038/s41591-024-03418.
PMID: 39753970